Clinical Trial

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 30, 2024 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
To assess the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-05-16; most recent amendment 2024-01-28.
Status change: Not Yet Recruiting → Recruiting 2022-12-06
Trial Details
NCT Number NCT05382728
Lead Sponsor TYK Medicines, Inc
Conditions NSCLC, EGFR Activating Mutation
Enrollment 680 participants
Start Date 2022-06-08
Primary Completion 2025-05 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-01-30